OTTAWA | For the third consecutive year, a KPMG study commissioned by Canada's Research-Based Pharmaceutical Companies (Rx&D) has determined that research and development investments made by Canada's innovative pharmaceutical sector continue to be consistently underreported, by approximately 34% for 2012.
A doctors’ groups that’s been a thorn in the side of the Ontario Medical Association in recent years has hired a controversial union leader to help grow its ranks.